Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies.

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Contemporary oncology increasingly focuses on evaluating multiple genomic alterations in tumor-driving pathways.
• Commercially available tumor panels utilizing next-generation sequencing (NGS) aim to create comprehensive molecular tumor blueprints.
• The goal is to match actionable variants with targeted therapies, irrespective of tumor origin.

Purpose of the Study:

• To review the current state of post-analytic processes for NGS tumor panels.
• To assess the existing evidence for the clinical validity of these panels in solid tumors.
• To highlight the need for new evidentiary standards for NGS-based oncology diagnostics.

Main Methods:

• Review of current literature on next-generation sequencing tumor panels.
• Analysis of data regarding post-analytic processes and clinical validity.
• Examination of existing research on treatment response and patient outcomes.

Main Results:

• Limited information is available on the post-analytic procedures specific to NGS platforms used in commercial tumor testing.
• Evidence demonstrating the clinical validity of genetic markers in these panels, linking them to treatment response for targeted therapies, is scarce across solid tumor types.
• No published data currently supports improved patient outcomes when using these commercial NGS tests for treatment guidance.

Conclusions:

• Next-generation sequencing tumor panels present unique challenges regarding analytical and clinical validity.
• Establishing robust evidentiary standards is crucial for evaluating the clinical utility of these tests in oncology.
• Further research is needed to validate NGS-based diagnostics and demonstrate their impact on clinical decision-making and patient outcomes.